Natco Pharma share price fell more than a percent in the opening trade on June 20 after the company received seven observations in the Form-483 from US Food and Drug Administration (USFDA).
At 09:24am, Natco Pharma was quoting at Rs 870.45, down Rs 10.90, or 1.24 percent, on the BSE.
The company announced conclusion of USFDA inspection at its pharma division located at Kothur, Hyderabad, India, which was conducted from June 9-19, 2025.
On conclusion of the inspection, the company received seven observations in the Form-483 and confident to address the observations within the stipulated timeline, company said in its release.
Company remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.
Catch all the market action on our live blog
On June 13, the Company received one observation in the Form-483 from USFDA on completing inspection at the API manufacturing plant located in Mekaguda, Hyderabad, India, which was conducted from June 9-13, 2025.
The share touched a 52-week high of Rs 1,638.35 and a 52-week low of Rs 660.05 on 12 September, 2024 and 07 April, 2025, respectively.
Currently, the stock is trading 46.21 percent below its 52-week high and 33.53 percent above its 52-week low.
The market capitalisation of the company stands at Rs 15,590.62 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
